Aldevron Breakthrough Blog

A Complete Suite of rAAV Constructs

March 16, 2022 / by Jeff Briganti

New ITR Cloning and Reporter Constructs Now Available
By Jeff Briganti, Senior Director, Global Strategic Marketing


Manufacturing standardization for cell and gene therapies (C&GT) has received increased focus in the last several years, spurred by the rapid exponential growth witnessed in this field. The resulting need for improved access to high-quality raw materials, including plasmid DNA, has made standardization integral to streamlining the development process for this biologic product category.

For recombinant adeno-associated virus (rAAV) viral vector production, we now offer several off-the-shelf ITR cloning backbones and GFP reporter constructs to complement our standardized set of OTS helper and packaging plasmids. This product set is available license and royalty free for research through commercial rAAV applications.

Utilizing this standardized portfolio can provide significant time and cost reduction, expediting time to market and de-risking specialized, transformative therapeutic development. By partnering with a contract development and manufacturing organization (CDMO) offering a complete suite of plasmids for viral vector production, researchers can streamline their upfront development while minimizing supply chain disruption throughout their program’s lifecycle.

For full information about our new product offering or to request a sample, visit our pALD-ITR Products page.

ABOUT THE AUTHOR

Jeff Briganti

Jeff Briganti is the Sr. Director of Global Strategic Marketing at Aldevron. Briganti has nearly 30 years of combined sales and marketing experience in the Life Science Research space. He holds a B.S. and an MBA from the University of Wisconsin, Madison. Before joining Aldevron in 2021, Briganti held numerous positions at Thermo Fisher Scientific, Promega, DNASTAR, and as an independent consultant. Most recently, Briganti served as Director of Marketing Development for Thermo Fisher Scientific’s Molecular Biology business unit.